Artelo Biosciences公布了一项非临床骨关节炎研究的结果,该研究支持其候选药物Art26.12成为治疗慢性疼痛的潜在首创新疗法。这项研究为Art26.12的开发提供了重要的临床前数据支持。
Artelo Biosciences公布了一项非临床骨关节炎研究的结果,该研究支持其候选药物Art26.12成为治疗慢性疼痛的潜在首创新疗法。这项研究为Art26.12的开发提供了重要的临床前数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.